Non-IgM monoclonal gammopathy of undetermined significance

Clinical trials for Non-IgM monoclonal gammopathy of undetermined significance explained in plain language.

Never miss a new study

Get alerted when new Non-IgM monoclonal gammopathy of undetermined significance trials appear

Sign up with your email to follow new studies for Non-IgM monoclonal gammopathy of undetermined significance, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1 Not yet finished but already full! 1

Could a common antibiotic stop a blood cancer before it starts?

Disease control Recruiting now

This study tests whether the antibiotic rifaximin can reduce abnormal proteins in people with a precancerous blood condition called IgA MGUS. About 50 adults will either receive the drug or no treatment. The goal is to see if rifaximin can lower the risk of progression to multipl…

Matched conditions: NON-IGM MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE

Phase 2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control

Last updated Aug 19, 2026 00:00 UTC

Non-IgM monoclonal gammopathy of undetermined significance

Get alerted when new Non-IgM monoclonal gammopathy of undetermined significance trials appear

Could a common antibiotic stop a blood cancer before it starts?